Ascendis Pharma AS

ASND · Moat type: REGULIERUNG

MoatScore

4/10

Fair Value

n/a

Margin of Safety

n/a

Rating

SCHWACH

Ascendis Pharma develops and markets endocrinological and oncological therapeutics based on a proprietary TransCon technology that releases active pharmaceutical ingredients through chemical binding in a time-delayed manner, thereby extending dosing intervals.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.